What is claimed is:

1. An antibody or fragment thereof that binds to a sudden acute respiratory syndrome coronavirus 2 (CoV) Spike (S) glycoprotein, wherein the antibody or fragment thereof comprises:

(i) a variable light chain complementarity-determining region 1 (VL CDR1) with at least 80 %, at least 85 %, at least 90 %, at least 95 %, or 100 % identity to a sequence selected from the group consisting of SEQ ID NOS: 11-14 and 76;

(ii) a variable light chain complementarity-determining region 2 (VL CDR2) with at least 80 %, at least 85 %, at least 90 %, at least 95 %, or 100 % identity to a sequence selected from the group consisting of SEQ ID NOS: 15-18 and 77;

(iii) a variable light chain complementarity-determining region 3 (VL CDR3) with at least 80 %, at least 85 %, at least 90 %, at least 95 %, or 100 % identity to a sequence selected from the group consisting of SEQ ID NOS: 19-22 and 78;

(iv) a variable heavy chain complementarity-determining region 1 (VH CDR1) with at least 80 %, at least 85 %, at least 90 %, at least 95 %, or 100 % identity to a sequence selected from the group consisting of SEQ ID NOS: 23-26 and 79;

(v) a variable heavy chain complementarity-determining region 2 (VH CDR2) with at least 80 %, at least 85 %, at least 90 %, at least 95 %, or 100 % identity to a sequence selected from the group consisting of SEQ ID NOS: 27-30 and 80; and

(vi) a variable heavy chain complementarity-determining region 3 (VH CDR3) with at least 80 %, at least 85 %, at least 90 %, at least 95 %, or 100 % identity to a sequence selected from the group consisting of SEQ ID NOS: 31-34 and 81.

2. An antibody or fragment thereof that binds to a sudden acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike (S) protein, wherein the antibody or fragment thereof comprises:

(i) a variable heavy (VH) domain comprising an amino acid sequence with at least 80 %, at least 81 %, at least 82 %, at least 83 %, at least 84 %, at least 85 %, at least 86 %, at least 87 %, at least 88 %, at least 89 %, at least 90 %, at least 91 %, at least 92 %, at least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 %, at least 99 %, or 100 % identity to a polypeptide of SEQ ID NOS: 5-8 and 75; and

(ii) a variable light (VL) domain comprising an amino acid sequence with at least 80 %, at least 81 %, at least 82 %, at least 83 %, at least 84 %, at least 85 %, at least 86 %, at least 87 %, at least 88 %, at least 89 %, at least 90 %, at least 91 %, at least 92 %, at least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 %, at least 99 %, or 100 % identity to a polypeptide of any one of SEQ ID NOS: 1-4 and 74.

3. The antibody or fragment thereof of claim 1, wherein the antibody or fragment thereof comprises:

(i) a variable heavy (VH) domain comprising an amino acid sequence with at least 80 %, at least 81 %, at least 82 %, at least 83 %, at least 84 %, at least 85 %, at least 86 %, at least 87 %, at least 88 %, at least 89 %, at least 90 %, at least 91 %, at least 92 %, at least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 %, at least 99 %, or 100 % identity to a polypeptide of SEQ ID NOS: 5-8 and 75; and

(ii) a variable light (VL) domain comprising an amino acid sequence with at least 80 %, at least 81 %, at least 82 %, at least 83 %, at least 84 %, at least 85 %, at least 86 %, at least 87 %, at least 88 %, at least 89 %, at least 90 %, at least 91 %, at least 92 %, at least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 %, at least 99 %, or 100 % identity to a polypeptide of any one of SEQ ID NOS: 1-4 and 74.

4. The antibody or fragment thereof of claim 2, wherein the antibody or fragment thereof comprises:

(i) a variable light chain complementarity-determining region 1 (VL CDR1) with at least 80 %, at least 85 %, at least 90 %, at least 95 %, or 100 % identity to a sequence selected from the group consisting of SEQ ID NOS: 11-14 and 76;

(ii) a variable light chain complementarity-determining region 2 (VL CDR2) with at least 80 %, at least 85 %, at least 90 %, at least 95 %, or 100 % identity to a sequence selected from the group consisting of SEQ ID NOS: 15-18 and 77;

(iii) a variable light chain complementarity-determining region 3 (VL CDR3) with at least 80 %, at least 85 %, at least 90 %, at least 95 %, or 100 % identity to a sequence selected from the group consisting of SEQ ID NOS: 19-22 and 78;

(iv) a variable heavy chain complementarity-determining region 1 (VH CDR1) with at least 80 %, at least 85 %, at least 90 %, at least 95 %, or 100 % identity to a sequence selected from the group consisting of SEQ ID NOS: 23-26 and 79;

(v) a variable heavy chain complementarity-determining region 2 (VH CDR2) with at least 80 %, at least 85 %, at least 90 %, at least 95 %, or 100 % identity to a sequence selected from the group consisting of SEQ ID NOS: 27-30 and 80; and

(vi) a variable heavy chain complementarity-determining region 3 (VH CDR3) with at least 80 %, at least 85 %, at least 90 %, at least 95 %, or 100 % identity to a sequence selected from the group consisting of SEQ ID NOS: 31-34 and 81.

5. The antibody or fragment thereof of of claim 4, wherein the antibody or fragment thereof is selected from the group consisting of:a VH CDR1 according to SEQ ID NOS: 23-26, 79, a VH CDR2 according to SEQ ID NOS: 27-30, 80, a VH CDR3 according to SEQ ID NOS: 31-34,81, a VL CDR1 according to SEQ ID NOS: 11-17, 76, a VL CDR2 according to SEQ ID NOS: 15-18, 77; and a VL CDR3 according to SEQ ID NOS: 19-22, 78.

6. The antibody or fragment thereof of claim 4, wherein the antibody or fragment thereof is selected from the group consisting of:

(i) a VH comprising the amino acid sequence of SEQ ID NOS:5-8, 75; and

(ii) a VL comprising the amino acid sequence of SEQ ID NOS: 1-4, 74.

7. The antibody or fragment thereof of claim 4, wherein the antibody or fragment thereof is a monoclonal antibody, a Fab, $F(ab')_2$, Fab′, a scFv, or a single domain antibody (sdAb).

8. The antibody or fragment thereof of claim 4, wherein the antibody comprises a human IgG1 or IgG4 domain.

9. The antibody or fragment thereof of claim 4, wherein the antibody or fragment thereof has an equilibrium dissociation constant (K_D) for a CoV S glycoprotein or

variant thereof of 50 nM or less, 10 nM or less, 1 nM or less, 0.5 nM or less, 0.1 nM or less, 0.05 nM or less, 0.01 nM or less, or 0.001 nM or less.

10. The antibody or fragment thereof of claim 4, wherein the antibody or fragment thereof binds to a CoV S glycoprotein or variant thereof with an equilibrium dissociation constant (Kd) of less than 1.0×10^{-9} moles per liter (M), less than 1.0×10^{-10} M, less than 1.0×10^{-11} M, or less than 1.0×10^{-12} M.

11. The antibody or fragment thereof of claim 4, wherein the antibody or fragment thereof binds to one or more CoV S polypeptides with at least 80 %, at least 81 %, at least 82 %, at least 83 %, at least 84 %, at least 85 %, at least 86 %, at least 87 %, at least 88 %, at least 89 %, at least 90 %, at least 91 %, at least 92 %, at least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 %, at least 99 %, or 100 % identity to a polypeptide according to any one of SEQ ID NOS: 9, 10, 35-43, 72-73, 90-139, and 145-147.

12. The antibody or fragment thereof of claim 4, wherein the antibody or fragment thereof binds to an epitope on a CoV S glycoprotein, wherein the epitope comprises amino acids 476, 485, 486, 487, and 489 of the CoV S glycoprotein of SEQ ID NO: 10.

13. The antibody or fragment thereof of claim 4, wherein the antibody or fragment thereof binds to an epitope on a CoV S glycoprotein, wherein the epitope comprises amino acids 378 and 385 of the CoV S glycoprotein of SEQ ID NO: 10.

14. The antibody or fragment thereof of claim 4, wherein the antibody or fragment thereof binds to an epitope on a CoV S glycoprotein, wherein the epitope comprises amino acids 444, 445, 446, and 448 of the CoV S glycoprotein of SEQ ID NO: 10.

15. A pharmaceutical composition, comprising an antibody or fragment thereof of claim 4 and a pharmaceutically-acceptable carrier.